Dr. Roper joined Epidarex Capital as a Partner in 2013. She has more than 15 years experience in the Life Science and Healthcare industry, primarily in venture capital fund management and industry where she successfully executed transactions both as a direct investor and as a business development executive. Prior to joining Epidarex, Dr. Roper was the head of Business Development at Chroma Therapeutics, an Oxford-based venture-backed drug discovery and development company focused on inflammatory disorders and oncology. Dr. Roper was involved in all key company strategic decisions and successfully established a number of major company-building alliances. These included a multi‐target deal with GlaxoSmithKline (GSK) around Chroma’s novel platform. She is a former executive with the Life Science venture capital team at the Investments Division of The Wellcome Trust. In this role, Dr. Roper provided direct early-stage equity financing to private companies in the Life Sciences industry in the US and Europe. Her investments included Fovea Pharmaceuticals, Nabriva Therapeutics and Sirtris Pharmaceuticals. She is also a former member of the Life Science team at Atlas Ventures, London. Dr. Roper holds a B.Sc. (Hons) in Biochemistry (1st class) from the University College Cork, and a Ph.D. from the Imperial Cancer Research Fund.